Genovis
Genovis AB is a Swedish biotechnology company specializing in the development of innovative enzymes that facilitate the analysis and characterization of antibodies and biological drugs. The company utilizes its proprietary SmartEnzymes technology to produce specialized enzymes, such as IdeS and FabRICATOR, which are widely used by biopharmaceutical researchers in drug discovery, antibody engineering, and quality control of biological medicines. Its core operations encompass biotechnology research, enzyme manufacturing, protein engineering, and global life science product distribution. Revenue is derived directly from the global sale of specialized enzymes and research reagents to academic institutions and pharmaceutical corporations. Genovis holds a specialized global market position in antibody-cleaving enzyme technology. The company is headquartered in Lund, Sweden, and its shares trade on Nasdaq Stockholm.
6 of the funds FundTelligence covers report a position in Genovis.
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 6
Funds holding Genovis
- Nordea Innovation Sustainable Stars — Nordea Funds · 4.6 % (full portfolio disclosed, June 2026)
- TIN Ny Teknik — Tin Fonder · 4.32 % (full portfolio disclosed, June 2026)
- Case All Star Småbolag — Case · 2.3 % (full portfolio disclosed, June 2026)
- Schroder ISF Nordic Micro Cap — Schroders · 0.94 % (full portfolio disclosed, June 2026)
- Schroder ISF Nordic Smaller Companies — Schroders · 0.63 % (full portfolio disclosed, June 2026)
- Nordea Nordic — Nordea Funds · 0.06 % (full portfolio disclosed, September 2026)